Drug detection test kit

plasmaurinetissue

[Intended use] Non-small cell lung cancer caused by activating mutations in the epidermal growth factor receptor gene (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is limited because of the emergence of drug resistance conferred by a second mutation, such as T790M. This kit detects 6 drug resistance mutations in exons 20 and 21 of the EGFR gene in non-small cell lung cancer patents The kits can be used for 1) early discovering and monitoring of acquired drug resistance, and 2) selection of targeted therapy. [Detection principle] This kit uses pyrophosphorolysis activated polymerization (PAP ) technology to specifically amplify the mutant DNA but not wildtype DNA molecules. The amplified product is measured in real time fluorescence format. [Samples] Fresh and frozen tissues, paraffin-embedded tissues, plasma and urine. [Advantages] 1. High sensitivity: ability to detect a single copy of EGFR mutations. 2. High specificity: virtually no false positive amplifications even in the presence of heavy background of wildtype DNA. 3.Freeze-dried format: much earlier and user-friendly manipulation. 4. Non-invasive sampling: plasma and urine samples can be applied.